telehealth.helpFind my match

Home WikiTelehealth Medications

Mounjaro

From WikiTelehealth, the telehealth.help reference · Last updated

Mounjaro is Eli Lilly's brand of tirzepatide for type 2 diabetes, approved by the FDA on May 13, 2022, as the first medicine that acts on both the GIP and GLP-1 receptors. It is a once-weekly injection and is not approved for weight loss.

Mounjaro
TypeGIP and GLP-1 receptor agonist
Generic nameTirzepatide
ManufacturerEli Lilly
First approvedMay 13, 2022 (US)
Approved forType 2 diabetes (ages 10+); heart risk reduction in type 2 diabetes
FormWeekly injection
Related brandZepbound

Approval history

The FDA approved Mounjaro on May 13, 2022, to improve blood sugar control in adults with type 2 diabetes, along with diet and exercise. It was the first approved dual GIP and GLP-1 receptor agonist. The approval was based on the SURPASS trial program.

The current label also covers children aged 10 and older with type 2 diabetes. On August 28, 2026, the FDA added a lower risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes who are at high risk of these events, based on the SURPASS-CVOT trial, which compared tirzepatide with dulaglutide.

Mechanism of action

Mounjaro contains tirzepatide, a single molecule that activates two receptors: the GLP-1 receptor and the receptor for GIP. Both hormones help release insulin when blood sugar is high. Tirzepatide also lowers appetite and slows stomach emptying, which is why it leads to weight loss.

Relation to Zepbound

Mounjaro and Zepbound contain the same molecule in the same doses. Mounjaro is labeled for type 2 diabetes, and Zepbound is labeled for weight management and sleep apnea. Use of Mounjaro for weight alone is off-label.

For how tirzepatide compares with semaglutide, including the head-to-head SURMOUNT-5 trial, see our semaglutide vs. tirzepatide comparison.

Forms, doses and side effects

Mounjaro comes in single-dose pens, single-dose vials, multi-dose vials and multi-dose KwikPens, with weekly doses from 2.5 mg to 15 mg. The label raises the dose in 2.5 mg steps, and the top dose for children is lower than for adults.

The most common side effects of Mounjaro are nausea, diarrhea, decreased appetite, vomiting, constipation and stomach pain. The label carries a boxed warning about thyroid C-cell tumors seen in rodent studies.

Timeline

  1. May 13, 2022FDA approves Mounjaro for type 2 diabetes in adults.
  2. November 8, 2023Tirzepatide approved for weight management under the name Zepbound.
  3. December 2025Label extended to children aged 10 and older with type 2 diabetes.
  4. August 28, 2026Cardiovascular risk reduction added, based on SURPASS-CVOT.

Compare semaglutide and tirzepatide

See also

References

  1. Mounjaro (tirzepatide) injection, original prescribing information, FDA 2022. accessdata.fda.gov
  2. Mounjaro (tirzepatide) prescribing information, DailyMed 2026. dailymed.nlm.nih.gov
  3. FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, Eli Lilly press release, August 28, 2026

Last updated . Category: Medications. Browse all 38 WikiTelehealth entries.